Article
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
Blood - 1 May 2004
Lozanski Gerard, Heerema Nyla A, Flinn Ian W, Smith Lisa, Harbison Jennifer, Webb Jennifer, Moran Mollie, Lucas Margaret, Lin Thomas, Hackbarth Marcy L, Proffitt John H, Lucas David, Grever Michael R, Byrd John C
Abstract excerpt
The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti-CD52 antibody alemtuzumab was effective in this patient group. Thirty-six patients with fludarabine-refractory CLL w...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.